Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT05368207

Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient

Conditions: Small Cell Carcinoma, Hypercalcaemic Type, Ovarian Cancer

Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: NA
Enrollment: 1
Sponsor: University Health Network, Toronto

Location: Princess Margaret Cancer Centre Toronto Ontario

Summary

This is a study of pembrolizumab as consolidation therapy for a patient with small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).

Eligibility Criteria

Inclusion Criteria: * Patient with small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) Exclusion Criteria: * N/A

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05368207). StuddyBuddy aggregates publicly available trial information.